<DOC>
	<DOCNO>NCT02520063</DOCNO>
	<brief_summary>This study test well new combination three drug ( Letrozole , Everolimus , TRC105 ) tolerate well work Stage 2 3 breast cancer give prior definitive surgery . Letrozole block estrogen receptor express many breast cancer everolimus block signal drive cancer cell grow . TRC105 investigational drug block formation growth blood vessel fee cancer promote growth . The goal study investigate safety efficacy multitargeted approach breast cancer .</brief_summary>
	<brief_title>Preoperative Combination Letrozole , Everolimus , TRC105 Postmenopausal Hormone-Receptor Positive Her2 Negative Breast Cancer</brief_title>
	<detailed_description>In postmenopausal woman hormone receptor-positive Her2 negative non-metastatic breast cancer , downstaging achievement complete pathologic remission definitive surgery associate low risk recurrence breast cancer . In order achieve good response patient preoperative setting , study combine 3 potentially synergistic agent . Letrozole block synthesis estrogen , , deprive tumor hormone drive growth . Everolimus drug block growth factor signal essential tumor cell maintain growth proliferation . Everolimus already show work well subtype breast cancer recurrent metastatic setting . TRC105 investigational agent prevents formation growth new blood vessel support tumor provide oxygen nutrient . The study 2 component . First investigator determine ideal term tolerance combination dose 3 agent . Once ideal regimen determine , patient treat investigational combination . During second stage , investigator get preliminary idea effective investigational therapy . Further study need do confirm efficacy investigational combination .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Recent diagnosis hormone receptor positive HER2 negative breast cancer . Stage 2 3 hormone receptor positive HER2 negative breast cancer ( stage T24 inflammatory , N02 , M0 ) . Histological grade I , II III accord modify Bloom Richardson scale . No prior treatment specific breast cancer . Postmenopausal status define National Comprehensive Cancer Network . ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % ) . Must sign studyspecific inform consent . Liver Function Tests &lt; 2.5 time upper normal limit ( UNL ) . ANC ≥ 1,500/mm3 , platelet ≥ 100,000/mm3 , Hemoglobin ≥ 10g % . Renal function : serum creatinine &lt; 1.5 institutional UNL creatinine clearance &gt; 40 cc/min . Inflammatory breast cancer . Pre perimenopausal state . Pregnancy . Metastatic disease . HER2 positive breast cancer immunohistochemistry FISH . Triple negative breast cancer ( hormone receptor Her2 negative ) . Disease follow image study .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hormone-receptor positive breast cancer</keyword>
	<keyword>Her2 negative breast cancer</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>everolimus</keyword>
	<keyword>TRC105</keyword>
	<keyword>letrozole</keyword>
</DOC>